Trelagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, serving as an active pharmaceutical ingredient (API) for the treatment of type 2 diabetes. It inhibits DPP-4 to increase levels of incretin hormones (e.g., GLP-1), which stimulate glucose-dependent insulin secretion from pancreatic beta cells and reduce glucagon production from alpha cells, thereby improving glycemic control.

This specialty chemical offers a long half-life, supporting once-weekly dosing for enhanced patient adherence compared to daily DPP-4 inhibitors. It is typically used in combination with diet, exercise, and other antidiabetic therapies. Trelagliptin is well-tolerated with a low risk of hypoglycemia but requires renal function monitoring, with dose adjustments for impaired kidney function.

As a high-purity reagent (≥99%), it is supplied as a white solid, verified by NMR, IR spectroscopy, and HPLC purity analysis. Ideal for pharmaceutical research, drug development, and analytical standards in diabetes-related studies.